Does Rallies show Form 4 insider transactions for APYX?

Yes. Rallies tracks APYX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is APYX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for APYX. It does not provide personalized investment advice.

APYX (Apyx Medical Corporation Common Stock) Stock Analysis - Insider Trades

Apyx Medical Corporation Common Stock (APYX) is a publicly traded Healthcare sector company. As of May 21, 2026, APYX trades at $3.79 with a market cap of $162.05M and a P/E ratio of -14.02. APYX moved -4.57% today. Year to date, APYX is +7.06%; over the trailing twelve months it is +154.36%. Its 52-week range spans $0.76 to $4.50. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces APYX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading APYX stock inside the company?

Recent APYX insider activity includes HILL MATTHEW C bought 6.00K, HILL MATTHEW C bought 5.34K, HILL MATTHEW C bought 2.50K, Goodwin Charles D. II bought 50.00K, and Hornsby Todd sold 15.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

APYX Key Metrics

Key financial metrics for APYX
Metric	Value
Price	$3.79
Market Cap	$162.05M
P/E Ratio	-14.02
EPS	$-0.27
Dividend Yield	0.00%
52-Week High	$4.50
52-Week Low	$0.76
Volume	0
Avg Volume	0
Revenue (TTM)	$52.84M
Net Income	$-11.11M
Gross Margin	62.53%

Recent APYX Insider Trades

HILL MATTHEW C bought 6.00K (~$6.78K) on Aug 13, 2024.
HILL MATTHEW C bought 5.34K (~$6.03K) on Aug 13, 2024.
HILL MATTHEW C bought 2.50K (~$5.47K) on Dec 12, 2023.
Goodwin Charles D. II bought 50.00K (~$78.50K) on Nov 14, 2023.
Hornsby Todd sold 15.00K (~$113.40K) on Jun 26, 2023.

Latest APYX News

Renuvion Combined with Liposuction Yields 50% Fewer Abdominoplasties, Higher Body-Q — May 14, 2026
Apyx Secures FDA Clearance for AYON System Power Liposuction Feature — May 11, 2026
Apyx’s Renuvion Wins NewBeauty Award and Shows Q1 Margin Improvement — May 7, 2026
Apyx Medical raises FY2026 revenue guidance after 32% Q1 sales jump — May 7, 2026

APYX Analyst Consensus

3 analysts cover APYX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.

Common questions about APYX

Who is trading APYX stock inside the company?: Recent APYX insider activity includes HILL MATTHEW C bought 6.00K, HILL MATTHEW C bought 5.34K, HILL MATTHEW C bought 2.50K, Goodwin Charles D. II bought 50.00K, and Hornsby Todd sold 15.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for APYX?: Yes. Rallies tracks APYX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is APYX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for APYX. It does not provide personalized investment advice.